[go: up one dir, main page]

PH12021050442A1 - ANTIPEPTIDE IMMUNOGLOBULINS TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2) SPIKE GLYCOPROTEIN (S PROTEIN) EPITOPES AND COGNATE IMMUNOGENS, METHODS FOR PRODUCING AND UTILIZING THE SAME, AND ANTIGEN DETECTION SYSTEMS RELATING THERETO - Google Patents

ANTIPEPTIDE IMMUNOGLOBULINS TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2) SPIKE GLYCOPROTEIN (S PROTEIN) EPITOPES AND COGNATE IMMUNOGENS, METHODS FOR PRODUCING AND UTILIZING THE SAME, AND ANTIGEN DETECTION SYSTEMS RELATING THERETO

Info

Publication number
PH12021050442A1
PH12021050442A1 PH1/2021/050442A PH12021050442A PH12021050442A1 PH 12021050442 A1 PH12021050442 A1 PH 12021050442A1 PH 12021050442 A PH12021050442 A PH 12021050442A PH 12021050442 A1 PH12021050442 A1 PH 12021050442A1
Authority
PH
Philippines
Prior art keywords
immunoglobulins
epitopes
producing
methods
antipeptide
Prior art date
Application number
PH1/2021/050442A
Inventor
Riziel Hannah B Aguimatang
Salvador Eugenio C Caoili
Fresthel Monica M Climacosa
Ayra Patrice N Espiritu
Ruby Anne N King
Original Assignee
Univ Of The Philippines Through The Univ Of The Philippines Manila
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Of The Philippines Through The Univ Of The Philippines Manila filed Critical Univ Of The Philippines Through The Univ Of The Philippines Manila
Priority to PH1/2021/050442A priority Critical patent/PH12021050442A1/en
Priority to PCT/PH2022/050014 priority patent/WO2023022613A2/en
Publication of PH12021050442A1 publication Critical patent/PH12021050442A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention provides: antipeptide immunoglobulins recognizing epitopes within the subdomain SD2 major disulfide loop of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein (S protein); cognate oligopeptide-based immunogenic constructscomprising said epitopes; methods for producing said immunoglobulins and said constructs; methods and systems for detecting antigens comprising said epitopes; use of said constructs for producing said immunoglobulins; and use of said immunoglobulins for detecting said antigens.
PH1/2021/050442A 2021-08-13 2021-08-13 ANTIPEPTIDE IMMUNOGLOBULINS TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2) SPIKE GLYCOPROTEIN (S PROTEIN) EPITOPES AND COGNATE IMMUNOGENS, METHODS FOR PRODUCING AND UTILIZING THE SAME, AND ANTIGEN DETECTION SYSTEMS RELATING THERETO PH12021050442A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PH1/2021/050442A PH12021050442A1 (en) 2021-08-13 2021-08-13 ANTIPEPTIDE IMMUNOGLOBULINS TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2) SPIKE GLYCOPROTEIN (S PROTEIN) EPITOPES AND COGNATE IMMUNOGENS, METHODS FOR PRODUCING AND UTILIZING THE SAME, AND ANTIGEN DETECTION SYSTEMS RELATING THERETO
PCT/PH2022/050014 WO2023022613A2 (en) 2021-08-13 2022-08-13 Antipeptide immunoglobulins to severe acute respiratory syndrome coronavirus 2 (sars-cov-2) spike glycoprotein (s protein) epitopes and cognate immunogens, method for producing and utilizing the same, and antigen detection systems relating thereto

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PH1/2021/050442A PH12021050442A1 (en) 2021-08-13 2021-08-13 ANTIPEPTIDE IMMUNOGLOBULINS TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2) SPIKE GLYCOPROTEIN (S PROTEIN) EPITOPES AND COGNATE IMMUNOGENS, METHODS FOR PRODUCING AND UTILIZING THE SAME, AND ANTIGEN DETECTION SYSTEMS RELATING THERETO

Publications (1)

Publication Number Publication Date
PH12021050442A1 true PH12021050442A1 (en) 2023-06-05

Family

ID=85241155

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2021/050442A PH12021050442A1 (en) 2021-08-13 2021-08-13 ANTIPEPTIDE IMMUNOGLOBULINS TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2) SPIKE GLYCOPROTEIN (S PROTEIN) EPITOPES AND COGNATE IMMUNOGENS, METHODS FOR PRODUCING AND UTILIZING THE SAME, AND ANTIGEN DETECTION SYSTEMS RELATING THERETO

Country Status (2)

Country Link
PH (1) PH12021050442A1 (en)
WO (1) WO2023022613A2 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3007090A1 (en) * 2014-10-09 2016-04-13 Strelnikov, Evgeny Immunogenic synthetic oligopeptides
EP4087606A1 (en) * 2020-01-09 2022-11-16 The University of Queensland Self-assembling, self-adjuvanting system for delivery of vaccines

Also Published As

Publication number Publication date
WO2023022613A2 (en) 2023-02-23
WO2023022613A3 (en) 2023-03-30

Similar Documents

Publication Publication Date Title
Boyoglu-Barnum et al. Prophylaxis with a respiratory syncytial virus (RSV) anti-G protein monoclonal antibody shifts the adaptive immune response to RSV rA2-line19F infection from Th2 to Th1 in BALB/c mice
PH12022552500A1 (en) Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
SG10201809694PA (en) Antibody neutralizing human respiratory syncytial virus
PE20040554A1 (en) VACCINES INVOLVING FUSION PROTEINS
MX2020009825A (en) Precision glycoconjugates as therapeutic tools.
GR3036229T3 (en) Method for the production of antihuman antigen receptors and uses thereof
BR0111823A (en) Polypeptide, vaccine, method for immunizing an animal against a pathogen, method for identifying antigenic polypeptide, antibody, or at least an effective part thereof, vector, cell, method for producing antibody, hybridoma cell line, and, use of antibodies.
ATE542829T1 (en) VACCINE
UA93855C2 (en) Neutralizing epitope-based growth enhancing vaccine
WO2009154995A3 (en) Interleukin 10 receptor (il-10r) antibodies and methods of use
EP2563385A4 (en) METHODS OF USING SOLUBLE CD24 FOR THE THERAPY OF RHEUMATOID ARTHRITIS
WO2005120565A3 (en) Sars vaccines and methods to produce highly potent antibodies
WO2021249012A9 (en) Coronavirus vaccine compositions, methods, and uses thereof
PH12022553653A1 (en) Construction and application of fusion protein vaccine platform
MX2025005092A (en) Anti-trem2 antibody and uses thereof
MX2024006506A (en) VACCINES BASED ON HUMAN METAPNEUMOVIRUS VIRAL VECTORS.
Ngu et al. In vivo targeting of protein antigens to dendritic cells using anti‐DEC‐205 single chain antibody improves HIV Gag specific CD4+ T cell responses protecting from airway challenge with recombinant vaccinia‐gag virus
PH12021050442A1 (en) ANTIPEPTIDE IMMUNOGLOBULINS TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2) SPIKE GLYCOPROTEIN (S PROTEIN) EPITOPES AND COGNATE IMMUNOGENS, METHODS FOR PRODUCING AND UTILIZING THE SAME, AND ANTIGEN DETECTION SYSTEMS RELATING THERETO
WO2022020636A3 (en) Immunogens derived from sars-cov2 spike protein
MX2022016494A (en) Anti-il13rî±2 antibodies.
DE60216906T8 (en) ANTI-PILYROSPORUM OVALE IGY AND ITS USE
PH12021050256A1 (en) ANTIPEPTIDE IMMUNOGLOBULINS RECOGNIZING NONGLYCOSYLATED EPITOPES WITHIN THE AMINO-TERMINAL EXTRAMEMBRANOUS DOMAIN OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2) MEMBRANE GLYCOPROTEIN (M PROTEIN) AND COGNATE OLIGOPEPTIDE-BASED IMMUNOGENIC CONSTRUCTS, METHODS FOR PRODUCING AND UTILIZING THE SAME, AND SYSTEMS RELATING THERETO FOR THE DETECTION OF ANTIGENS COMPRISING SAID EPITOPES
WO2006071896A3 (en) Epitope-based sars vaccine
Ibañez et al. Genetic and subunit vaccines based on the stem domain of the equine influenza hemagglutinin provide homosubtypic protection against heterologous strains
WO2023019174A3 (en) Antibodies to sars-cov-2